PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.40 +0.00 (+0.25%)
As of: Nov 12, 2026 · 2:06 PM EST

PharmaCyte Biotech (PMCB) Sale and Maturity of Investments (2009)

Updated

Analysis

PharmaCyte Biotech (PMCB) Sale and Maturity of Investments (2009) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 308.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 405.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - 88.00 Mn
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 2.53 Bn
10 PharmaCyte Biotech 4.29 Mn -68.55 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jul 31, 2009 24,967.00
Apr 30, 2009 -17,185.00
API Access

PharmaCyte Biotech Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=PMCB&period=max&api_key=YOUR_API_KEY